natgillin/translations-raw huggingface dataset:
Patients infected with a virus that has the ‘YMDD mutation’ (a change in the virus’s DNA that is often found after treatment with lamivudine) should take Lamivudine Teva in combination with another medicine against hepatitis B. For more information, please see the Summary of Product Characteristics (also part of the EPAR).
Bolniki, okuženi z YMDD mutacijo virusa (tj. spremembo v virusni DNK, ki je pogosta po zdravljenju z lamivudinom), morajo zdravilo Lamivudine Teva jemati v kombinaciji z drugim zdravilom proti hepatitisu B. Za več informacij glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
Patients infected with HCV genotype 2 or 3 who have detectable HCV RNA at week 4, regardless of pre-treatment viral load should receive 24 weeks of therapy.
Bolnike, okužene s HCV genotipom 2 ali 3, ki imajo merljivo koncentracijo HCV RNA v 4. tednu, zdravimo 24 tednov, ne glede na virusno breme pred začetkom zdravljenja.
Patients infected with HIV-1 with resistance to the integrase class (documented or clinically suspected)
Bolniki, okuženi z virusom HIV-1, z odpornostjo na zdravila iz skupine zaviralcev integraze (dokumentirano ali klinično domnevne)
Patients infected with HIV-1 without documented or clinically suspected resistance to the integrase class
Bolniki, okuženi z virusom HIV-1, brez dokumentirane ali klinično domnevne odpornosti na zdravila iz skupine zaviralcev integraze
Patients infected with pre-XDR-TB
bolniki s pre-XDR-TB
Patients infected with viral genotypes 2 or 3 should receive 24 weeks of treatment, while patients infected with any other genotype should receive 48 weeks of therapy.
Bolniki, okuženi z virusnim genotipom 2 ali 3, naj bi prejeli 24 tedensko zdravljenje, bolniki, okuženi z drugimi genotipi, pa 48 tednov zdravljenja.
Patients initiated on ramipril 10 mg had a higher rate of BCAR (15%) compared to patients initiated on ramipril 5 mg (5%).
Pri bolnikih, ki so začeli prejemati 10 mg ramiprila, je bil delež tistih z BCAR večji (15 %) kot pri bolnikih, ki so začeli prejemati 5 mg ramiprila (5 %).
Patients involved in the placebo-controlled study had an MMSE (Mini-Mental State Examination) score of 10–20.
Bolniki, vključeni v s placebom kontrolirano študijo, so imeli rezultat MMSE (Mini-Mental State Examination – kratek preizkus spoznavnih sposobnosti) med 10 in 20.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10 – 24.
Rezultat MMSE (Mini-Mental State Examination) pri bolnikih, ki so sodelovali v tej študiji je bil 10 – 24.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10-24.
Bolniki, vključeni v to študijo, so imeli rezultat MMSE (Mini-Mental State Examination – kratek preizkus spoznavnih sposobnosti) med 10 in 24.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10-24.
Bolniki, vključeni v to študijo, so imeli rezultat MMSE (Mini-Mental State Examination – kratek preskus spoznavnih sposobnosti) med 10 in 24.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10–24.
Bolniki, vključeni v to študijo, so imeli rezultat MMSE (Mini-Mental State Examination – kratek preizkus spoznavnih sposobnosti) med 10 in 24.
Patients involved should be preferably naïve to the history of thalidomide.
Prednost se daje bolnikom, ki do sedaj še niso bili zdravljeni s talidomidom.
Patients known to be CYP2C9 poor metabolisers should be treated with caution (see section 5.2).
Bolnike, za katere je znano, da slabo presnavljajo s CYP2C9, je treba zdraviti previdno (glejte poglavje 5.2).
Patients less than 18 years of age must be vaccinated against Haemophilus influenzae and pneumococcal infections, and strictly need to adhere to the national vaccination recommendations for each age group.
Bolniki, mlajši od 18 let, morajo biti cepljeni proti Haemophilus influenzae in proti pnevmokoknim okužbam, in dosledno upoštevati nacionalna priporočila glede cepljenja za vsako starostno skupino.
Patients less than 18 years of age must be vaccinated against Haemophilus influenzae and pneumococcal infections.
Bolniki, mlajši od 18 let, morajo biti cepljeni proti okužbam s Haemophilus influenzae in pnevmokokom.
Patients less than 18 years of age.
Bolniki mlajših od 18 let.
Patients less than 40 kg
bolniki s telesno maso manj kot 40 kg
Patients less than 40 kg*
bolniki s telesno maso manj kot 40 kg
Patients less than 40 kg**
bolniki s telesno maso manj kot 40 kg
Patients may also need to take calcium and vitamin D supplements if they do not have enough from their diet.
Bolnice lahko po potrebi jemljejo tudi dodatke kalcija in vitamina D, če ju ne dobivajo dovolj s prehrano.
Patients may also need to take medicines to prevent vomiting before taking Temozolomide Sun.
Pred zaužitjem zdravila Temozolomide Sun bodo bolniki morda morali vzeti tudi zdravila, ki preprečujejo bruhanje.
Patients may also receive calcium and vitamin D supplements if they do not get enough from their diet.
Bolnice lahko po potrebi jemljejo tudi dodatek kalcija in vitamina D, če ju ne dobijo dovolj s prehrano.
Patients may also receive calcium and vitamin D supplements if they do not get enough from their diet.
Bolnice lahko po potrebi jemljejo tudi kalcij in vitamin D, če ju ne dobivajo dovolj s prehrano.
Patients may be at an increased risk for the development of gastrointestinal perforation and gall bladder perforation when treated with Avastin.
Bolniki so lahko izpostavljeni večjemu tveganju za nastanek perforacije prebavil in žolčnika, če se zdravijo z zdravilom Avastin.
Patients may be at increased risk for the development of fistulae when treated with Avastin.
Bolniki so lahko izpostavljeni večjemu tveganju za nastanek fistule, če se zdravijo z zdravilom Avastin.
Patients may be at risk of developing venous thromboembolic reactions, including pulmonary embolism under Avastin treatment.
Med zdravljenjem z zdravilom Avastin so bolniki lahko podvrženi povečanemu tveganju za razvoj venskih trombemboličnih neželenih učinkov, vključno s pljučno embolijo.
Patients may be counted in more than one row. dICH=intracranial haemorrhage. eClinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but <5 g/dL.
Bolniki so lahko našteti v več kot eni vrsti. d ICH=intracranial haemorrhage, intrakranialna krvavitev. e Klinično očitna krvavitev, povezana s padcem hemoglobina ≥ 3 g/dl vendar < 5 g/dl.
Patients may be counted in more than one row. e ICH=intracranial haemorrhage. f Clinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but <5 g/dL.
Bolniki so lahko našteti v več kot eni vrsti. e ICH=intracranial haemorrhage, intrakranialna krvavitev. f Klinično očitna krvavitev, povezana s padcem hemoglobina ≥ 3 g/dl vendar < 5 g/dl.
Patients may be given other medicines during treatment with Humira, such as corticosteroids (other anti-inflammatory medicines).
Bolnikom se med zdravljenjem z zdravilom Humira lahko dajejo tudi druga zdravila, kot so kortikosteroidi (druga protivnetna zdravila).
Patients may be unresponsive to the usual doses of adrenaline used to treat the allergic reactions.
Bolniki so lahko neodzivni na običajne odmerke adrenalina, ki se uporabljajo za zdravljenje alergijskih reakcij.
Patients may continue therapy during periods of reversible, chemotherapy-induced myelosuppression butthey should be monitored carefully for complications of neutropenia during this time.
Bolniki lahko nadaljujejo zdravljenje tudi med obdobji reverzibilne mielosupresije, ki je posledica kemoterapije, vendar pa jih je v tem času treba skrbno spremljati zaradi zapletov nevtropenije.
Patients may develop antibodies to Plegridy.
Pri bolnikih se lahko razvijejo protitelesa proti zdravilu Plegridy.
Patients may display disproportionate weight increase.
Pri bolniku se lahko telesna masa nesorazmerno poveča.
Patients may experience discontinuation symptoms after cessation from an SSRI/ SNRI antidepressant.
Po prenehanju zdravljenja z antidepresivom iz skupine SSRI/SNRI se lahko pri bolnikih pojavijo odtegnitveni simptomi.
Patients may experience reactions (for example dizziness or nausea) during treatment, which might affect the ability to drive and use machines.
Bolniki lahko med zdravljenjem doživijo neželene učinke (na primer omotica ali slabost), kar lahko vpliva na sposobnost vožnje in upravljanja s stroji.
Patients may have allergic or hypersensitivity reactions to MabCampath and to murine or chimeric monoclonal antibodies.
Bolniki lahko doživijo alergijske ali preobčutljivostne reakcije na zdravilo MabCampath in na murina ali himerna monoklonska protitelesa.
Patients may have increased susceptibility to infections, especially with encapsulated bacteria.
Bolniki so lahko bolj dovzetni za okužbe, zlasti z enkapsuliranimi bakterijami.
Patients may need to take Daxas for several weeks before it starts to have an effect.
Bolniki morajo jemati zdravilo Daxas več tednov, preden se pokaže njegov učinek.
Patients may notice a taste when using Aerivio Spiromax due to the lactose excipient.
Bolniki bodo med uporabo zdravila Aerivio Spiromax v ustih občutili okus zaradi pomožne snovi laktoze.
Patients may notice a taste when using Aerivio Spiromax due to the lactose excipient.
Bolniki bodo med uporabo zdravila Airexar Spiromax v ustih občutili okus zaradi pomožne snovi laktoze.
Patients may receive 2 cycles of treatment.
Bolniki lahko dobijo 2 ciklusa zdravljenja.
Patients may require debridement of the hypertrophic tissue via arthroscopy.
Bolniki bodo morda potrebovali presaditev hipertrofičnega tkiva z artroskopskim postopkom.
Patients may store the pens at room temperature, not exceeding 30C, for no more than a total of 4 weeks prior to use.
Bolniki lahko peresnike shranjujejo na sobni temperaturi, ki ne presega 30 C, a ne več kot skupaj 4 tedne pred uporabo.
Patients must be administered with the following premedications 45-90 minutes prior to Empliciti infusion (see section 4.4):
Bolniki morajo od 45 do 90 minut pred infundiranjem zdravila Empliciti prejeti premedikacijo z naslednjimi zdravili (glejte poglavje 4.4):
Patients must be advised that tenofovir disoproxil fumarate has not been proven to prevent the risk of transmission of HBV to others through sexual contact or contamination with blood.
Bolniki morajo biti poučeni o tem, da zdravljenje z dizoproksiltenofovirijevim fumaratom ne preprečuje tveganja za prenos HBV na druge preko spolnega stika ali okužbe s krvjo.
Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with Abilify Maintena.
Bolnicam je treba svetovati, da morajo obvestiti svojega zdravnika, če med zdravljenjem z aripiprazolom zanosijo ali nameravajo zanositi.
Patients must be appropriately hydrated prior to administration of Zoledronic Acid Hospira.
Preden bolniki dobijo zdravilo Zoledronska kislina Hospira, morajo biti primerno hidrirani.
Patients must be assessed prior to administration of Zoledronic acid Teva to ensure that they are adequately hydrated.
Pred uporabo zdravila Zoledronska kislina Teva moramo bolnike oceniti, da zagotovimo, da so ustrezno hidrirani.
Patients must be assessed prior to administration of zoledronic acid to ensure that they are adequately hydrated.
Pred uporabo zoledronske kisline je potrebno bolnike oceniti, za zagotovitev ustrezne hidratacije.
Patients must be assessed prior to administration of Zometa to ensure that they are adequately hydrated.
Pred uporabo zdravila Zometa moramo bolnike oceniti, da zagotovimo, da so ustrezno hidrirani.
Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period.
Med obdobjem infundiranja morate bolnike natančno nadzorovati in skrbno opazovati, da lahko ugotovite, če se bo pojavil kakšen simptom.
Patients must be given a patient alert card containing important safety information and must be informed by their doctor about the risks of Caprelsa.
Bolniki morajo prejeti opozorilno kartico za bolnike, ki vsebuje pomembne informacije o varnosti, zdravnik pa jim mora pojasniti tveganja, povezana z zdravilom Caprelsa.
Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with Oprymea.
Bolnike je treba nanje opozoriti in jim svetovati, naj bodo med zdravljenjem s pramipeksolom previdni pri vožnji in upravljanju strojev.
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between NovoRapid and other insulin products.
Bolnikom je treba naročiti, da pred vsakim injiciranjem vedno preverijo nalepko na viali/vložku/injekcijskem peresniku in tako preprečijo nenamerno zamenjavo zdravila NovoRapid in drugih insulinskih zdravil.
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Tresiba and other insulin products.
Bolnike je treba opozoriti, da pred injiciranjem vedno preverijo nalepko insulina, da po pomoti ne zamenjajo zdravila Tresiba in drugih insulinskih zdravil.
Patients must be instructed to report any symptoms suggestive of endophthalmitis or any of the above mentioned events without delay, e.g. eye pain, blurred vision etc. (see section 4.8).
Bolnikom je treba naročiti, naj takoj poročajo o kakršnih koli simptomih, ki kažejo na endoftalmitis, ali o katerih koli zgoraj omenjenih dogodkih, npr. bolečini v očesu, zamegljenem vidu ipd. (glejte poglavje 4.8).
Patients must be maintained well hydrated prior to and following administration of Zoledronic acid medac 4 mg/100 ml.
Bolniki morajo biti pred dajanjem zdravila Zoledronska kislina medac 4 mg/100 ml in po njem dobro hidrirani.
Patients must be maintained well hydrated prior to and following administration of zoledronic acid.
Bolniki morajo biti pred dajanjem zoledronske kisline in po njej dobro hidrirani.
Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Flixabi.
Pred, med in po zdravljenju z zdravilom Flixabi morate bolnike skrbno spremljati, da ugotovite morebitne okužbe, npr. tuberkulozo.
Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Inflectra.
Pred, med in po zdravljenju z zdravilom Inflectra morate bolnike skrbno spremljati, da ugotovite morebitne okužbe, npr. tuberkulozo.
Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Remicade.
Pred, med in po zdravljenju z zdravilom Remicade morate bolnike skrbno spremljati, da ugotovite morebitne okužbe, npr. tuberkulozo.
Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Remsima.
Pred, med in po zdravljenju z zdravilom Remsima morate bolnike skrbno spremljati, da ugotovite morebitne okužbe, npr. tuberkulozo.
Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Simponi.
Bolnike je treba natančno spremljati, da ugotovite morebitne okužbe, vključno s tuberkulozo, pred, med in po zdravljenju z zdravilom Simponi.
Patients must be monitored closely for signs and symptoms of tuberculosis during and after treatment with Ilaris.
Bolnike je treba med zdravljenjem z zdravilom Ilaris in po njem natačno spremljati glede znakov in simptomov tuberkuloze.
Patients must be monitored during treatment to check their blood levels of platelets (components that help the blood to clot) and neutrophils (the white blood cells that fight infection).
Bolnike je treba med zdravljenjem spremljati, in sicer preverjati njihove ravni trombocitov (sestavine v krvi, ki pomaga pri njenem strjevanju) v krvi in nevtrofilcev (belih krvnih celic, ki se borijo proti okužbam).
Patients must be monitored for bronchial hyperresponsiveness to inhaled mannitol during their initiation dose assessment before commencing the therapeutic dose regimen of Bronchitol.
Bolnike je treba med oceno začetnega odmerka pred uvedbo terapevtskega režima odmerjanja zdravila Bronchitol spremljati za bronhialno hiperodzivnost na inhalirani manitol.
Patients must be monitored for gastrointestinal signs and symptoms that may be indicative of immune- related colitis or gastrointestinal perforation.
Bolnike je treba nadzirati glede pojava znakov in simptomov v prebavilih, ki bi lahko kazali na pojav imunsko pogojenega kolitisa ali perforacije v prebavilih.
Patients must be vaccinated or revaccinated according to current national vaccination guidelines for vaccination use.
Bolniki morajo prejeti cepljenje ali obnovitveno cepljenje v skladu z veljavnimi nacionalnimi smernicami za cepljenje.
Patients must have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumour) before Lynparza treatment is initiated.
Pred uvedbo zdravljenja z zdravilom Lynparza morajo imeti bolnice potrjeno mutacijo gena BRCA (gen dovzetnosti za raka dojk), bodisi germinalno bodisi v tumorju.
Patients must not have been infected with HIV that was unlikely to respond to any of the three active substances in Atripla before they started their first HIV treatment combination.
Preden bolniki začnejo jemati prvo kombinacijo zdravil ne smejo biti okuženi z vrsto virusa HIV za katero ni verjetno, da se bo odzvala na katero koli zdravilno učinkovino v zdravilu Atripla.
Patients must not receive further Gazyvaro infusions if they experience:
Bolniki ne smejo dobiti nadaljnih infuzij zdravila Gazyvaro, če se pri njih pojavi oziroma pojavijo:
Patients must take oral folic acid or a multivitamin containing folic acid (350 – 1,000 µg) on a daily basis.
Bolniki morajo dnevno jemati peroralno folno kislino ali multivitaminski pripravek, ki jo vsebuje (350 – 1000 µg).
Patients must visually verify the number of selected units on the dose counter of the pen.
Bolniki morajo z ogledom preveriti število izbranih enot na števcu odmerka injekcijskega peresnika.
Patients must wait at least 4 hours before treating another episode of BTP with PecFent.
Bolniki morajo počakati vsaj 4 ure po odmerku, preden vzamejo nov odmerek zdravila PecFent za zdravljenje naslednje epizode BTP.
Patients naïve to immunoglobulin therapy
Bolniki, ki še niso prejemali imunoglobulinskega zdravljenja
Patients need to be assessed for their immunity to varicella (chickenpox) prior to Gilenya treatment.
Pred začetkom zdravljenja z zdravilom Gilenya je treba pri bolnikih oceniti, ali so imuni na virus noric.
Patients need to be instructed that insulin glargine 100 units/ml products and Toujeo are not interchangeable and dose adjustments need to be made;
Bolnikom je treba povedati, da zdravila z insulinom glarginom 100 enot/ml in zdravilo Toujeo niso medsebojno zamenljivi in da je treba odmerek prilagoditi.
patients not adequately controlled on a lower strength corticosteroid combination product
bolniki, pri katerih simptomi niso pod ustreznim nadzorom s kombiniranim zdravilom, ki vsebuje kortikosteroid manjše jakosti
Patients not currently treated with an erythropoiesis stimulating agent (ESA):
Bolniki, ki se trenutno ne zdravijo z zdravili za stimulacijo eritropoeze
Patients not on dialysis require the lower starting dose: 3 tablets daily, in separated doses, with or immediately after meals of the day.
Bolniki, ki niso na dializi, potrebujejo manjši začetni odmerek: 3 tablete na dan, v ločenih odmerkih, ob obrokih ali takoj po njih.
Patients not receiving antiretroviral therapy
Bolniki, ki niso prejeli protiretrovirusnega zdravljenja
Patients not reported to have successful eschar removal
Bolniki, pri katerih niso poročali o uspešni odstranitvi eshar
Patients not required to have tissue biopsy to determine RET status for enrolment
Bolniki, pri katerih za vključitev ni potrebno opraviti biopsije tkiva za določitev statusa RET
Patients not taking levodopa (early stage of Parkinson’s disease)
Bolniki, ki ne jemljejo L-dope (zgodnja faza Parkinsonove bolezni)
Patients not using inhaled steroids
Bolniki, ki ne uporabljajo inhalacijskih steroidov
Patients of 4 years of age and older unable to swallow capsules: The dose will be calculated according to your weight by your doctor.
Bolniki, stari 4 leta in starejši, ki ne zmorejo pogoltniti kapsul: Glede na vašo težo bo odmerek preračunal zdravnik.
Patients of age ≥75 years were more likely to experience Grade 3 or 4 hypertension, proteinuria, decreased appetite, and dehydration.
Pri bolnikih, starih 75 let ali več, so bile verjetnejše hipertenzija, proteinurija, zmanjšan apetit in dehidracija stopnje 3 ali 4.
Patients of age ≥75 years, of Asian race, with comorbidities (such as hypertension, and hepatic or renal impairment), or body weight below 60 kg appear to have reduced tolerability to lenvatinib (see section 4.8, Other special populations).
Zdi se, da starejši bolniki, stari 75 let ali več, ki pripadajo azijski rasi in imajo sočasne druge bolezni (na primer hipertenzijo in okvaro jeter ali ledvic) ali telesno maso, ki je manjša od 60 kg, slabše prenašajo lenvatinib (glejte poglavje 4.8, Druge posebne skupine bolnikov).
Patients of black African or Afro-Caribbean ancestry should therefore be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen whilst using Aerivio Spiromax.
Bolnikom črnega afriškega ali afrokaribskega porekla je treba zato naročiti, da zdravljenje nadaljujejo, vendar se posvetujejo z zdravnikom, če astme še naprej ne morejo nadzorovati ali če se med uporabo salmeterola/flutikazonpropionata pojavi poslabšanje.
Patients of child-bearing potential should be advised to use effective contraception while on treatment.
Bolnice v rodni dobi naj med zdravljenjem uporabljajo ustrezno kontracepcijo.
Patients of non- Caucasian origin have not been included in these clinical studies.
V tej klinični študiji niso bili vključeni bolniki, ki niso kavkaškega porekla.
patients of these acetate origins are tested positive for HLA- B*1502 allele, the use of eslicarbazepine acetate may be considered if the benefits are thought to exceed risks.
Če so testi pri bolnikih tega porekla pozitivni za alel HLA- B*1502, je mogoče o uporabi eslikarbazepinacetata razmisliti, če so pričakovane koristi večje od tveganj.
Patients of weight > 55 kg
maso > 55 kg
Patients older than 50 years of age (n=23) have been successfully treated with Busilvex without dose- adjustment.
Bolniki, starejši od 50 let (n = 23), so bili uspešno zdravljeni z zdravilom Busilvex brez prilagoditve odmerka.
Patients older than 50 years of age (n=23) have been successfully treated with busulfan without dose- adjustment.
Bolniki, starejši od 50 let (n = 23), so bili uspešno zdravljeni z busulfanom brez prilagoditve odmerka.
Patients older than 65 years have an increased risk of experiencing the following side effects :
Pri bolnikih, starejših od 65 let, je večje tveganje za naslednje neželene učinke:
Patients older than 75 years may be at a higher risk of respiratory related adverse events such as pleural effusion and dyspnoea
Bolniki, starejši od 75 let, so morda bolj ogroženi, kar zadeva neželene učinke, povezane z dihanjem, kot so plevralni izliv in dispneja.
Patients on a controlled sodium diet must take this into consideration.
To morajo upoštevati bolniki, ki so na dieti z nadzorovanim vnosom natrija.
Patients on ambrisentan therapy should be closely monitored when starting treatment with rifampicin (see sections 4.4 and 5.2).
Bolnike, ki prejemajo ambrisentan, je treba ob uvedbi zdravljenja z rifampicinom natančno kontrolirati (glejte poglavji 4.4 in 5.2).
Patients on an atazanavir/ritonavir-based regimen
Bolniki na osnovni shemi atazanavir/ritonavir
Patients on an efavirenz-based regimen
Bolniki na osnovni shemi z efavirenzom
Patients on antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin) (see section 4.5)
Zdravljenje z antidepresivi, ki vplivajo na prevajanje impulzov v noradrenergičnem živčnem sistemu (npr. tricikličnimi antidepresivi in mianserinom) (glejte poglavje 4.5).
Patients on Brinavess must not be given medicines called ‘class I and III anti-arrhythmics’ intravenously during the four hours before or after their Brinavess infusion.
Bolniki štiri ure pred infundiranjem zdravila Brinavess in štiri ure po njem ne smejo intravensko prejemati zdravil, imenovanih „antiaritmitiki razreda I in III .